News | Image Guided Radiation Therapy (IGRT) | June 14, 2018

Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac

Next-generation cancer therapy enables delivery of higher, potentially more effective radiation dose regimens

Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac

June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has begun treating patients with Viewray's second-generation magnetic resonance (MR) image-guided radiotherapy system, the MRIdian Linac. Siteman is the first U.S. cancer center to offer cancer therapy with both MRIdian and MRIdian Linac.

Washington University physicians and researchers at Siteman played an integral role in the development, testing and clinical introduction of MRIdian in 2012. The first cancer patients worldwide to receive MR-guided radiation therapy were treated at Siteman.

Unlike conventional radiotherapy, MRIdian Linac technology uses high-definition MR soft-tissue imaging to visualize and track the detailed contours of the tumor and adjacent healthy tissues. The enhanced visibility allows clinicians to quickly and dynamically adjust the prescribed radiation dose distribution when the tumor moves during the course of treatment. The combined capabilities provide clinicians with the tools to improve targeting precision and thus deliver higher and potentially more effective radiation doses, while simultaneously minimizing incidental radiation exposure to surrounding organs.

"We know that tumors and their surrounding anatomy naturally change position from day to day — even during treatment — making it vitally important that we see where the radiation dose is being delivered in real-time," said Jeff Bradley, M.D., the S. Lee Kling Professor of Radiation Oncology at Washington University. "The clarity and detail afforded by MRI combined with this new technology allows us to target tumors with a high level of accuracy regardless of changes or motion, further enabling us to expand our treatment options."

"As an institution actively involved in advancing MR image-guided therapy since the very beginning, we are excited to remain at the forefront with the addition of this latest innovation," said Jeff Michalski, M.D., professor and vice chair of the Department of Radiation Oncology at Washington University.

For more information: www.viewray.com

Related Content

The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | October 21, 2020
October 21, 2020 — According to an artic...
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...
Moffitt Cancer Center researchers are developing a noninvasive, accurate method to analyze a patient's tumor mutations and biomarkers to determine the best course of treatment.

Getty Images

News | Lung Imaging | October 19, 2020
October 19, 2020 — Personalized treatment options for patients with...
Varian, a leading provider of cancer care technologies and solutions, continues to reinforce its commitment to delivering Intelligent Cancer Care during the 2020 American Society for Radiation Oncology (ASTRO) taking place virtually Oct. 24-31.
News | ASTRO | October 19, 2020
October 19, 2020 — ...
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
Mevion Medical Systems announced that it has shipped the accelerator module for the Mevion S250i Proton Therapy System to Kunshan, China. The 15-ton compact accelerator, the heart of the proton therapy system, is the smallest of its kind and will be the first in China.

Mevion's compact accelerator module is lifted and placed on a truck for the first leg of its journey to China. (Photo: Business Wire)

News | Proton Therapy | October 16, 2020
October 16, 2020 — Mevion Medical Systems announced that it has shipped the accelerator module for the...